Introduction. We wanted to determine vitamin D status after gestational diabetes mellitus (GDM) and to evaluate whether levels of 25-hydroxyvitamin D 3 (25OHD 3 ) are associated with beta cell function, insulin resistance or a diagnosis of diabetes after GDM. Material and methods. Glucose homeostasis was assessed during a 75-g oral glucose tolerance test one to two years after delivery in 376 women with previous GDM (287 European and 78 nonEuropean, including 33 Arab and 35 Asian women). Insulin resistance was estimated using homeostasis model assessment of insulin resistance (HOMA-IR). The insulinogenic index (I/G30) and the disposition index [(I/G30)/ HOMA-IR] were used to calculate insulin secretion. Concentrations of serum 25OHD 3 were determined. Results. Mean (AESD) 25OHD 3 concentration was 50.0 AE 22.3 nmol/L and differed significantly among subgroups of body mass index, ethnicity, and glucose tolerance status; 53% had 25OHD 3 levels <50 nmol/L and 87% had 25OHD 3 levels <75 nmol/L. There was a negative correlation between 25OHD 3 concentration and HOMA-IR (p < 0.001) and a positive correlation between 25OHD 3 and disposition index (p = 0.002) in univariable regression analysis. Correlations attenuated after adjustment for body mass index. In univariable regression analysis, 25OHD 3 concentrations were significantly associated with diabetes after GDM (p = 0.004). However, in a multivariable model, non-European origin, HOMA-IR and insulinogenic index were significantly associated with postpartum diabetes, whereas 25OHD 3 concentrations were not. Conclusion. Vitamin D deficiency/insufficiency in previous GDM cases appears to be associated with beta cell dysfunction and insulin resistance, but not with postpartum diabetes when factors well known to influence type-2 diabetes were adjusted for.
Introduction
Gestational diabetes mellitus (GDM) and type-2 diabetes have many risk factors in common and they share the same metabolic characteristics. Both are characterized by insulin resistance and an inability of the beta cells to compensate by a sufficient increase in insulin secretion (1) . Serum 25-hydroxyvitamin D 3 (25OHD 3 ) is considered to be the most appropriate indicator of overall vitamin D status (2) . Preliminary data suggest that vitamin D is involved in glucose homeostasis. The mechanism ª 2017 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 96 (2017) 821-827 possibly involves both insulin secretion and insulin action (3) . Lower levels of 25OHD 3 have been associated with higher risk of type-2 diabetes and also the metabolic syndrome (4, 5) . Moreover, a recent meta-analysis revealed that maternal vitamin D insufficiency is associated with an increased risk of GDM (6) . However, the available evidence is limited and it is not clear whether the relation between vitamin D status and impairment of glucose metabolism is causal or whether it is related to confounding factors.
We have previously shown that Arab women with GDM are more insulin resistant during pregnancy than Scandinavian women are (7) . Furthermore, we recently reported from the prospective Mamma Study that women of nonEuropean origin had an increased frequency of diabetes one to two years after GDM, which was associated with increased insulin resistance -differently modulated by body mass index (BMI) in Arab and Asian women (8) .
The objective of the present study was to determine vitamin D status in women at the one-to two-year follow-up in the Mamma Study, and to evaluate whether levels of 25OHD 3 are associated with insulin resistance, beta cell dysfunction, and a diagnosis of diabetes after GDM. We hypothesized that ethnicity and BMI would account for part of the assumed associations, and that adjustment for these factors would attenuate the results.
Material and methods
The design of the Mamma Study has been described in detail elsewhere (9) . Briefly, pregnant women who gave birth in southern Sweden during the years 2003-2005 were followed prospectively to detect the development of diabetes. A 75-g oral glucose tolerance test (OGTT) was offered to all women in the 28th week of gestation, and also in gestational week 12 if they had a history of GDM in previous pregnancies or a first-degree relative with diabetes. The diagnostic criteria for GDM were those recommended by the World Health Organization (WHO) in 1999, defining GDM as a joint category of diabetes and impaired glucose tolerance (IGT) based on the two-hour plasma glucose concentration (10) . The one-to two-year examination included a standard 75-g OGTT with measurements of both glucose and insulin concentrations at 0, 30, and 120 min to enable calculation of indices of beta cell function and insulin resistance, as previously reported (8) . In conjunction with the OGTT at the oneto two-year follow-up, a blood sample for determination of 25OHD 3 concentration was collected and serum was stored at À20°C until analysis. In all, measurements of 25OHD 3 concentrations were successful in 376 women who had previously had GDM and who formed the basis of the present evaluation.
Based on the stated country of origin of at least three grandparents, women were grouped according to whether they were of European or non-European origin. From the definition used, 11 women with GDM were unclassifiable. The non-European group included the subgroups of Arab women (n = 33; Iraq, Lebanon, Morocco, Palestine, Somalia, and Syria), Asian women (n = 35; Afghanistan, China, India, Iran, Kurdistan, Pakistan, the Philippines, South Korea, Thailand, Turkey, and Vietnam), and women with other origins (n = 10; Berber, Bolivia, Brazil, Chile, Colombia, Eritrea, Ghana, Israel, Uganda, and Uruguay).
The WHO 1999 diagnostic criteria were used for classification of women during follow-up into those having normal glucose tolerance, impaired fasting glucose, impaired glucose tolerance, or diabetes (10). All women gave their written informed consent and the Ethics Committee of Lund University approved the study (LU 259-00, 2002-04-17), which was performed in accordance with the Declaration of Helsinki.
The HemoCue Glucose 201+ system (HemoCue AB, € Angelholm, Sweden) was used for immediate measurement of plasma glucose concentrations (in mmol/L). Serum insulin concentrations (mU/L) were measured with an enzyme-linked immunosorbent assay (Dako, Glostrup, Denmark). Homeostasis model assessment was used to estimate insulin resistance (HOMA-IR), i.e. (fasting serum insulin 9 fasting plasma glucose)/22.5 (11, 12) . Beta cell function was estimated using the insulinogenic index (I/G30), which is the ratio of the incremental insulin to glucose during the first 30 min of the OGTT, i.e.
(insulin 30 min À insulin 0 min )/(glucose 30 min À glucose 0 min ) (13) . As insulin resistance modulates insulin secretion, the disposition index was used to adjust insulin secretion for the degree of insulin resistance, obtained by dividing I/G30 by HOMA-IR (14) .
The serum concentration of 25OHD 3 (in nmol/L), which is stable in stored serum (15) , was determined by liquid chromatography mass spectrophotometry (LC-MS/ MS). Quality controls in two levels were analyzed at the start and end of every run with the following interassay
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Vitamin D deficiency/insufficiency is prevalent in previous gestational diabetes mellitus cases. 25OHD 3 levels correlate negatively with insulin resistance and postpartum diabetes, and positively with insulin secretion. These associations are interrelated and are influenced by other factors such as body mass index and ethnicity. coefficient of variation, respectively 4.4% at 36 nmol/L 25OHD 3 and 3.7% at 134 nmol/L 25OHD 3 . The LC-MS method was calibrated with Chromsystems (Munich, Germany) calibrators, which are directly traceable to the US National Institute of Standards and Technology. Assays were performed according to accredited methods at the Department of Clinical Chemistry, Sk ane University Hospital, Malm€ o, Sweden, which also participates in DEQAS, a vitamin D external quality assessment scheme.
Statistical analyses
Categorical variables are shown as n (%). Continuous variables are summarized as mean AE standard deviation (SD) if normally distributed or as median and interquartile range if skewed. Indices of insulin secretion and insulin resistance were log-transformed to obtain normality. Frequencies were compared between groups using Fisher's exact test. Analysis of variance (ANOVA) was used to test for differences between group means, and the Mann-Whitney U-test or the Kruskal-Wallis test was used to test for differences in medians. Women were classified into groups according to vitamin D status according to the Endocrine Society guidelines: deficiency (<50 nmol/L), insufficiency 50-74 nmol/L, and sufficiency ≥75 nmol/L (16) . Depending on the date of sample collection for vitamin D analysis, the results were grouped into months and seasons (winter, DecemberFebruary; spring, March-May; summer, June-August; autumn, September-November). The association between 25OHD 3 levels and measures of glucose homeostasis obtained during the OGTT was examined by univariable linear regression analysis, adjusted for BMI in the final model. Multivariable logistic regression analysis was used to estimate the association between 25OHD 3 and diabetes after GDM, using normal glucose tolerance/impaired fasting glucose/impaired glucose tolerance as reference, while adjusting for confounders that were associated with diabetes in univariable analysis (p < 0.05). In addition to 25OHD 3 , variables tested for associations with diabetes after GDM were age (years), BMI (kg/m 2 ), non-European vs. European origin (yes/ no), insulinogenic index, and HOMA-IR. We used IBM SPSS Statistics version 22 for Windows (IBM Corporation, Armonk, NY, USA) for analysis. Two-sided p-values of less than 0.05 were considered statistically significant.
Results
The mean (AESD) age of participating women was 34.3 AE 4.8 years; 79% were of European origin (79% Swedish) and 21% were of non-European origin. Levels of 25OHD 3 were compared among different subgroups ( Table 1) . The overall mean 25OHD 3 level was 50.0 AE 22.3 nmol/L, but the levels differed significantly between subgroups of BMI, ethnicity, glucose tolerance status, and season.
Of the 376 women, 53% had vitamin D deficiency (25OHD 3 <50 nmol/L), 33% had vitamin D insufficiency (25OHD 3 50-74 nmol/L), and 13% had vitamin D sufficiency (25OHD 3 ≥75 nmol/L). BMI, HOMA-IR, and disposition index differed significantly according to the level of 25OHD 3 , whereas insulinogenic index did not differ significantly ( Table 2 ). All the women with vitamin D sufficiency were of European origin. However, 82% of the European women had 25OHD 3 levels <75 nmol/L and 42% had 25OHD 3 levels <50 nmol/L. Of the 198 women with vitamin D deficiency, 51 had 25OHD 3 levels below 25 nmol/L, and 80% of them were of non-European origin.
Snuff was used in 1% of the women at follow-up, and 12% smoked. There were no significant differences in the frequencies of tobacco use between women in the different subgroups of glucose tolerance or vitamin D levels.
In univariable linear regression analysis, 25OHD 3 levels correlated negatively with HOMA-IR (p < 0.001) and positively with disposition index (p = 0.002), but not with insulinogenic index or fasting and two-hour glucose levels during the OGTT. However, when adjusting for BMI, 25OHD 3 levels were not statistically significantly associated with HOMA-IR or deposition index, although they approached significance for HOMA-IR (p = 0.053).
Altogether, 26 of 376 women were diagnosed with diabetes at the one-to two-year follow-up. In univariable logistic regression analysis, assessing 25OHD 3 as a continuous variable, 25OHD 3 levels were significantly associated with diabetes after GDM (p = 0.004). In the multivariable model, the relation between 25OHD 3 levels and diabetes was not significant, whereas non-European origin, HOMA-IR, and insulinogenic index were significantly associated with postpartum diabetes (Table 3) .
Discussion
This study confirmed what is known about the high prevalence of low levels of 25OHD 3 in women of childbearing age worldwide (17) ; 87% of the women had 25OHD 3 levels <75 nmol/L and 53% had 25OHD 3 levels <50 nmol/L. Overall, women of non-European origin had lower levels of 25OHD 3 after pregnancy than women of European origin. Furthermore, 80% of the women with extremely low vitamin D levels (25OHD 3 <25 nmol/L) were of non-European origin, whereas all women with vitamin D sufficiency were of European origin. These observations are supported by previous reports of poor vitamin D status in many immigrant populations in Europe relative to the indigenous populations (18 There are several possible explanations for the variation in vitamin D levels between ethnic groups, such as clothing habits, diet, vitamin D supplementation, and differences in melanin production when exposed to sunlight (20) .
When stratified by ethnicity, 82% of European women had vitamin D levels <75 nmol/L and 42% had vitamin D deficiency. This contrasts with the findings of Hedlund et al. (21), who reported corresponding figures of 69 and 23%, respectively, when they evaluated determinants of vitamin D status in a group of 84 non-pregnant, non-lactating, healthy, fair-skinned women of childbearing age living in the city of Gothenburg in Sweden. This discrepancy may reflect differences in study group characteristics, and also differences in laboratory methodology for 25OHD 3 assessment. As pointed out by the authors, the electro-chemiluminescent immunoassay used by them tends to give higher concentrations than the liquid chromatography mass spectrometry used in the present study.
To the best of our knowledge, this is the first study evaluating indices of insulin resistance and beta cell function during OGTT after GDM in relation to vitamin D status. Insulin resistance and impaired beta cell function contribute to the development of type-2 diabetes (1). Therefore, quantifying insulin sensitivity and insulin secretion are of great importance for the understanding of the disease. Indirect measurements using the HOMA-IR and the insulinogenic index are often used in epidemiological studies and have shown reasonable correlations with direct methods of measurements, which are more complex, labor-and time-consuming (11-13).
As expected, we found a significant association between 25OHD 3 levels and HOMA-IR. However, the association attenuated after adjustment for BMI. Low serum concentrations of 25OHD 3 have been associated with reduced insulin sensitivity, impaired glucose metabolism, and the metabolic syndrome (3) (4) (5) . The mechanism by which vitamin D affects insulin sensitivity is still unknown. Vitamin D may stimulate expression of insulin receptors in peripheral tissues, and thereby increase glucose transport (22) . Insulin-mediated glucose uptake is calcium-dependent, and therefore vitamin D status may indirectly influence glucose uptake (23) . Insulin sensitivity, measured by the hyperglycemic clamp technique, has been shown to correlate inversely with plasma parathyroid hormone (PTH) levels in healthy women (24) . Thus, it could be that ambient variation in PTH production is the key mediator of the insulin resistance associated with poor vitamin D status (25) . Unfortunately, we did not investigate PTH levels in the present study.
There is evidence to suggest that vitamin D affects insulin secretion (3) . The influence of vitamin D deficiency on insulin secretion could be mediated by the effect on calcium concentrations, as calcium ion fluxes have an essential role in insulin secretion from beta cells (23) . Alternately, it may relate to a secondary increase in PTH levels (26) . Fadda et al. examined the direct effect of PTH on insulin release from pancreatic islets in normal rats and found that PTH stimulated glucose-induced insulin release in a dose-dependent manner but that higher doses inhibited glucose-induced insulin release (27) . In the present study, we used the insulinogenic index and the disposition index -which are surrogate measures of first-phase insulin secretion -to evaluate whether vitamin D was associated with impaired insulin secretion. The disposition index, which adjusts insulin secretion for the degree of insulin resistance, was significantly associated with vitamin D levels, supporting the observation that vitamin D appears to affect insulin response upon glucose stimulation (28) .
Finally, we examined whether 25OHD 3 levels were associated with diabetes after GDM and found a significant association by univariable logistic regression analysis (p = 0.004). However, in the multivariable model, the relation between 25OHD 3 levels and diabetes was not significant, whereas HOMA-IR and insulinogenic index were highly significantly associated with diabetes after GDM. Since insulin resistance and impaired beta cell function are closely linked to the pathophysiology of type-2 diabetes, this could be expected, and a larger sample size is needed to rule out the possibility of an effect of vitamin D status on these measurements.
According to the Endocrine Society guidelines, pregnant and lactating women are candidates for screening for vitamin D deficiency. To satisfy the requirements to maintain a 25OHD 3 level above 30 ng/mL (74 nmol/L) it is recommended that their daily regimen should include a multivitamin containing 400 IU vitamin D with a supplement that contains at least 1000 IU vitamin D (16) . It is obvious from the literature that these guidelines are not followed by different countries in the world (17) . In Sweden, pregnant women are not generally screened for vitamin D status, or routinely prescribed vitamin D supplementation. Intervention studies have shown conflicting results regarding the beneficial effect of vitamin D supplementation on insulin secretion and insulin sensitivity (3). Large, well-controlled randomized studies are needed to evaluate the effect of adequate doses of vitamin D on glucose homeostasis and the overall health outcomes in pregnant women.
To our knowledge, there have been no studies investigating the possible effect of vitamin D deficiency/insufficiency during pregnancy with GDM on manifest postpartum diabetes. Kramer et al. (29) studied 524 women with a full spectrum of glucose tolerance in pregnancy, ranging from normal glucose tolerance to GDM. They found that increased PTH, rather than vitamin D deficiency/insufficiency, was independently associated with impaired glucose tolerance in pregnancy. Furthermore, vitamin D status was not found to be associated with insulin sensitivity, beta cell function, or gestational glucose tolerance. The authors highlighted the need for consideration of the PTH/25OHD axis when studying the effect of vitamin D status on glucose homeostasis (29) .
One strength of this study was that measures of beta cell function were derived from the OGTT. Assessment of beta cell function in the basal state by HOMA does not take first-phase insulin release into consideration and therefore gives a less reliable measure of beta cell function than provided by the insulinogenic index and disposition index (13) .
The present study also had some limitations. Although the number of study subjects was relatively large compared with other studies, it still lacked enough power to detect small potential effects of vitamin D on glucose homeostasis, insulin secretion, and insulin sensitivity. during pregnancy, only one to two years after pregnancy, on the same occasion as the diagnostic OGTT. Moreover, PTH was not analyzed.
In conclusion, low levels of 25OHD 3 were common in the present group of women of different ethnicity one to two years after GDM. Our results indicate that vitamin D deficiency/insufficiency appears to be associated with beta cell dysfunction and insulin resistance. However, no association was found between vitamin D levels and postpartum diabetes when adjusted for factors well known to influence the development of type-2 diabetes, such as BMI, ethnicity, and indices of beta cell function and insulin resistance.
